First study niraparib
WebAug 7, 2024 · The results of the study formed the evidence basis for approval of niraparib as the only oral, once-daily PARPi as monotherapy maintenance treatment for women with first-line platinum-responsive advanced ovarian cancer, regardless of biomarker status, in both the USA and EU, and more recently the United Kingdom (Fig. 4). WebJan 1, 2024 · This study f … The JASPER clinical trial studied a new combination treatment for advanced or metastatic non-small cell lung cancer (NSCLC). ... ≥50% (cohort 1) or 1%-49% (cohort 2) received first-line niraparib (200 mg once daily) plus pembrolizumab (200 mg every 3 weeks). The primary end point was investigator-assessed objective response ...
First study niraparib
Did you know?
WebNov 30, 2024 · A study of niraparib combined with MGD013 in patients with advanced or metastatic solid tumor who failed prior treatment. clinicaltrials.gov. Updated April 1, 2024. Accessed November 30, 2024 ... WebFeb 17, 2024 · Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.. Is this guidance up to date? More evidence on niraparib is being collected, until …
WebMar 1, 2024 · The NDA is supported by data from the MAGNITUDE study (NCT03748641), a Phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of niraparib plus AAP as a first-line treatment in patients with mCRPC, with or without alterations in HRR associated genes. 1 Patients with HRR gene … WebFeb 1, 2024 · Niraparib late-breaking data: · First results from the Phase 3 MAGNITUDE study of niraparib in combination with abiraterone acetate plus prednisone as a first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations (Abstract #12) …
WebMar 23, 2024 · The phase III MAGNITUDE study was designed to compare the efficacy and safety of niraparib + AAP versus placebo + AAP for first-line mCRPC. Clinical data have shown the efficacy of combining androgen receptor–targeted therapy and a PARP inhibitor in metastatic prostate cancer, but the patient population who could have an optimal … WebJul 2, 2024 · Study Description Go to Brief Summary: This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described …
WebJul 27, 2024 · A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of …
Web1 day ago · Niraparib, or the MAGNITUDE trial, looked at patients with metastatic CRPC for first-line therapy randomized to either ARPI or abiraterone versus abiraterone plus niraparib. Now, what's different of the MAGNITUDE study compared to the other two that have been recently reported now is that it had a prospective selection of the patients ... fish tanks in homesWebFeb 14, 2024 · 1 Chi et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant ... candy cantuWebOct 29, 2024 · European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer . For media and investors only. ... fish tanks in hospitalsWebSep 6, 2024 · The study had a single arm: All participants were prescribed niraparib 300 mg per day, which was given as oral capsules. In order to assess the effectiveness of … candy canyonWebFeb 16, 2024 · Chi et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. ASCO GU 2024. candy canonsburg paWeb1 day ago · In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. ... The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and ... candy cap 32WebSep 23, 2024 · The FDA approved niraparib for patients with HRD-positive advanced ovarian cancer in October 2024 based on data from the single-arm QUADRA Study (NCT02354586) evaluating the agent vs placebo. 1 ... candy cap 20